Denali Therapeutics Stock Forecast, Price & News

Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

Is Denali Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics or view top-rated stocks.

How has Denali Therapeutics' stock been impacted by COVID-19?

Denali Therapeutics' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DNLI stock has increased by 162.9% and is now trading at $44.37.
View which stocks have been most impacted by COVID-19.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Denali Therapeutics.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.69) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.23. The business had revenue of $5.29 million for the quarter, compared to the consensus estimate of $30.28 million. Denali Therapeutics had a net margin of 8.38% and a trailing twelve-month return on equity of 2.72%. The firm's quarterly revenue was down 43.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.54) earnings per share.
View Denali Therapeutics' earnings history.

What price target have analysts set for DNLI?

8 Wall Street analysts have issued 1 year price objectives for Denali Therapeutics' stock. Their forecasts range from $70.00 to $111.00. On average, they expect Denali Therapeutics' stock price to reach $93.29 in the next twelve months. This suggests a possible upside of 110.2% from the stock's current price.
View analysts' price targets for Denali Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:

• Ryan J. Watts, President, Chief Executive Officer & Director (LinkedIn Profile)
• Alexander O. Schuth, Chief Operating Officer & Secretary (LinkedIn Profile)
• Steve E. Krognes, Treasurer, Chief Financial & Accounting Officer (LinkedIn Profile)
• Carole Ho, Chief Medical Officer & Head-Development (LinkedIn Profile)
• Dana Andersen, CTO & Chief Manufacturing Officer

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics CEO Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among Denali Therapeutics' employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Denali Therapeutics' key competitors?

Some companies that are related to Denali Therapeutics include Bio-Techne (TECH), Novozymes A/S (NVZMY), argenx (ARGX), Ginkgo Bioworks (DNA), Repligen (RGEN), Novavax (NVAX), QIAGEN (QGEN), Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Exelixis (EXEL), Abcam (ABCM) and Fate Therapeutics (FATE).
View all of DNLI's competitors.

What other stocks do shareholders of Denali Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG).

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (12.34%), Crestline Management LP (6.31%), BlackRock Inc. (6.19%), Temasek Holdings Private Ltd (4.40%), Credit Suisse AG (1.62%) and Casdin Capital LLC (1.39%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends for Denali Therapeutics.

Which institutional investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Crestline Management LP, Wasatch Advisors Inc., Invesco Ltd., Jennison Associates LLC, Baillie Gifford & Co., Bamco Inc. NY, Marshall Wace LLP, and Two Sigma Investments LP. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato.
View insider buying and selling activity for Denali Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Denali Therapeutics stock?

DNLI stock was acquired by a variety of institutional investors in the last quarter, including Pathway Capital Management LP, Temasek Holdings Private Ltd, BlackRock Inc., Goldman Sachs Group Inc., Hamilton Lane Advisors LLC, Dimensional Fund Advisors LP, Moors & Cabot Inc., and Skandinaviska Enskilda Banken AB publ .
View insider buying and selling activity for Denali Therapeutics or or view top insider-buying stocks.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $44.37.

How much money does Denali Therapeutics make?

Denali Therapeutics has a market capitalization of $5.42 billion and generates $335.66 million in revenue each year. The company earns $71.14 million in net income (profit) each year or $0.14 on an earnings per share basis.

How many employees does Denali Therapeutics have?

Denali Therapeutics employs 291 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is www.denalitherapeutics.com.

Where are Denali Therapeutics' headquarters?

Denali Therapeutics is headquartered at 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (615) 866-8548 or via email at [email protected].